The use of vaccines affording long-term protective immune responses might be envisaged in HER-2-positive breast cancer, to prolong the (relatively) short-term efficacy of therapeutic regimes based on monoclonal antibodies. This evidence concerns the gene ERBB2 and breast carcinoma.